FDA Brief

Warning letters Drugs

FDA warning letter to

Omni Consumer Products LLC d/b/a YoKratom

High riskIssued Jun 30, 2022Posted Jul 5, 2022Center for Drug Evaluation and Research | CDER

FDA and FTC warned YoKratom that its kratom products are unapproved new drugs marketed to treat opioid addiction.

What happened

FDA reviewed https://yokratom.com/ in May 2022 and FTC reviewed it in June 2022. The agencies found that the website takes orders for Red Maeng Da, Red Borneo, Red Bali, White Maeng Da, and White Borneo kratom powder and capsule products and makes claims that they treat or cure opioid addiction and withdrawal. FDA says these claims make the products unapproved new drugs.

What FDA found

  1. The kratom products are unapproved new drugs because the website markets them to treat or cure opioid addiction and withdrawal.

    FD&C Act §§ 505(a), 301(d), 21 U.S.C. 355(a), 331(d)
  2. The products are drugs under the law because the website claims they are intended to treat disease or affect body function.

    FD&C Act § 201(g)(1), 21 U.S.C. 321(g)(1)
  3. The products are new drugs not generally recognized as safe and effective, and FDA says there are no approved applications for them.

    FD&C Act § 201(p), 21 U.S.C. 321(p); §§ 505(a), 301(d)
  4. The company advertised that kratom can treat or cure addiction without competent and reliable scientific evidence, as the FTC Act requires.

    FTC Act, 15 U.S.C. §§ 41–57

What FDA wants

FDA asks the company to notify it in writing within 15 working days of steps taken to correct the violations, with explanations and supporting documents, or to explain why it believes the products are not violations; FTC asks for notice within 15 working days of actions taken on its concerns.

Who should pay attention

  • kratom brands and online sellers
  • companies making opioid addiction or withdrawal claims
  • retailers and marketplaces listing kratom products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk